MedTrace Logo

Fibromyalgia During the COVID-19 Pandemic

NCT04422522 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2020-06-11

No results posted yet for this study

Summary

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019.

There is evidence of a high prevalence of psychiatric comorbidities in Fibromyalgia (FM )(especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome.

Conditions

  • Fibromyalgia, Primary

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Ahmed Abogamal · Al-Azhar Faculty of medicine- Cairo

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-15
Primary Completion
2020-05-15
Completion
2020-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422522 on ClinicalTrials.gov